Open original FDA record ↗Recall record
- FDA identifier
- Z-1048-2017
- Company in FDA record
- Endologix
- FDA classification date
- Jan 19, 2017
- First observed by MedTech Watch
- Nov 16, 2026
- Latest observed content change
- Nov 16, 2026
- Recall classification
- Class II
Reason stated in the source
Endologix updated information on the rates of Type III endoleaks and suggestions for patient surveillance and treatment.
Source facts
- Action
- Endologix sent a Dear Physician letter on 12/30/16 to inform them information related to the AFX Endovascular AAA System (AFX System). The letter provides updated information on the rates of Type III endoleaks and suggestions for patient surveillance and treatment. Customers were informed of the voluntary recall of the small remaining quantity of original AFX with Strata graft material, and the larger diameter sizes of AFX2. Customers with any questions are instructed to contact their Endologix representative. Customers with questions were instructed to call their Endologix representative. On 1/17/17, Endologix issued a press release to inform consumers that firm is resuming shipments of all sizes of AFX2 Endovascular AAA systems and appointed Laura Nagel as Vice President, Global Quality. Consumers are informed that the large diameter sizes of AFX2 were placed on temporary hold on 12/27/16 to investigate a manufacture issue.
- Initiated
- 2017-01-04
- Root cause
- Device Design
- Terminated
- 2017-04-28
- Distribution
- Worldwide Distribution - US (nationwide)and Internationally to Austria, Belgium, France, Germany, Greece, Italy, Ireland, Monaco, Poland Portugal, Romania, Spain, Sweden, Turkey, Israel, Argentina, Florida, Mexico, Chile, Brazil, Japan, Singapore, Malaysia, and Thailand.
- Recall number
- Z-1048-2017
- Recall status
- Terminated
- CDRH record ID
- 152594
- FDA classified
- 2017-01-19
- Recall event number
- 76256